title: Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
abstract: OBJECTIVE
  To compare persistence with medication and the reasons for discontinuation of mirabegron or solifenacin therapy up to12 months in women with overactive bladder (OAB).
  
  
  METHODS
  Female OAB patients who presented to women's urology clinics were enrolled in a prospective, randomized, two-arm study. Patients were randomized to receive mirabegron at 25-50 mg (n = 76) or solifenacin at 2.5-5 mg (n = 72). The persistence rate and the reasons for discontinuation were investigated up to 12 months.
  
  
  RESULTS
  The 12-month persistence rate was 12.2% in the mirabegron group versus 20.1% in the solifenacin group and there were no significant differences of the persistence rates during the study (n.s). Patients discontinued treatment because of lack of efficacy (21.6%), spontaneous improvement (18.2%), and side-effects (17.6%), while 19.6% were lost to follow up. Discontinuation due to side-effects was significantly more frequent in the solifenacin group than the mirabegron group (27.3 vs. 7.9%, P < 0.05). In contrast, discontinuation due to lack of efficacy was significantly more frequent in the mirabegron group than the solifenacin group (36.8 vs. 5.6%, P < 0.05).
  
  
  CONCLUSIONS
  This study demonstrated low persistence rates over 12 months for both mirabegron and solifenacin, although the reasons for discontinuation were somewhat different.
authors.affiliation: Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: Manami
authors.initials: M
authors.lastname: Kinjo
authors.affiliation: LUNA Pelvic Floor Total Support Clinic, Yokohama-shi, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Sekiguchi
authors.affiliation: Yotsuya Medical Cube, Tokyo, Japan.
authors.forename: Yasukuni
authors.initials: Y
authors.lastname: Yoshimura
authors.affiliation: Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: Kikuo
authors.initials: K
authors.lastname: Nutahara
mesh_terms: D000083:Acetanilides / Q000008:administration & dosage* / Q000009:adverse effects; D057915:Drug Substitution; D005260:Female; D006801:Humans; D008134:Long-Term Care; D017698:Postmenopause; D011446:Prospective Studies; D000069464:Solifenacin Succinate / Q000008:administration & dosage* / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D064804:Urological Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000083:Acetanilides; D013844:Thiazoles; D064804:Urological Agents; D000069464:Solifenacin Succinate; C520025:mirabegron
keywords: antimuscarinic agent; female; overactive bladder; persistence; β3-adrenoreceptor agonist